Jennison Associates’s Akero Therapeutics AKRO Stock Holding History

Jennison Associates’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-139,366	Closed	-$6.62M	–	579
2025 Q3	$6.62M	Buy	139,366 +62,503	+81%	+$3.03M	﹤0.01%	396
2025 Q2	$4.1M	Buy	76,863 +63,685	+483%	+$2.89M	﹤0.01%	414
2025 Q1	$533K	Buy	+13,178	New	+$559K	﹤0.01%	548

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jennison Associates's AKRO Position: Q4 2025 in Review

Jennison Associates sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 139,366 shares — an estimated $6.62M sold.

Jennison Associates first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $6.62M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Jennison Associates reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Jennison Associates sold 139,366 Akero Therapeutics shares in Q4 2025, an estimated $6.62M.
Jennison Associates first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Jennison Associates's Akero Therapeutics position peaked at $6.62M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.